Sopharma AD (the “Company”) announces that on 28 July 2015 the Company bought 937 000 ordinary registered shares with voting rights of the capital of United Holding Doverie AD. After this transaction, the share of Sopharma AD in the capital of United Holding Doverie AD increased to 14.898%.

Sopharma AD (the “Company”) hereby notifies that on 4 August 2015 Sopharma AD received a notification of disclosure of shareholdings from Telso AD regarding the selling of 397 057 shares. After this transaction the share of Telso AD in the capital of Sopharma AD decreased below 5%.The date of registration of the transaction with the Central Depository AD is 31 July 2015.

Sopharma AD notifies that for July 2015 the Company recorded a decrease of sales revenues of 27% compared to the same month of 2014, including same level of domestic sales and 56% decrease of export sales.
For the first seven months of this year, revenues from sales decreased by 18% compared to the same period of 2014, including 9% increase of domestic sales and a 30% decrease of export sales.

Sopharma AD (the “Company”) hereby notifies that on 3 August 2015 Sopharma AD received a notification of disclosure of shareholdings from Telekomplekt invest AD regarding the purchasing of 108 700 shares. After this transaction the share of Telekomplekt invest AD in the capital of Sopharma AD reached 20.07%.
The date of registration of the transaction with the Central Depository AD is 31 July 2015.

SOPHARMA AD hereby informs that from 29 July 2015 up to and including 05 August 2015 the Company bought 350 own shares representing 0.00026% of the share capital of the Company, at a total value of 975.90 BGN on the Bulgarian Stock Exchange, the average price per share was 2.703 BGN.

The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.

The total number of treasury shares after these transactions is 5 175 182, representing 3.84% of the share capital of the Company.

SOPHARMA AD hereby informs that from 20 August 2015 up to and including 26 August 2015 the Company bought 500 own shares representing 0.0004% of the share capital of the Company, at a total value of 1320.00 BGN on the Bulgarian Stock Exchange, the average price per share was 2.64 BGN.

The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.

The total number of treasury shares after these transactions is 5 175 682, representing 3.84% of the share capital of the Company.

Sopharma AD notifies that for August 2015 the Company recorded an increase of sales revenues of 1% compared to the same month of 2014, including 5% decrease of domestic sales and 4% increase of export sales.

For the first eight months of this year, revenues from sales decreased by 15% compared to the same period of 2014, including 9% increase of domestic sales and a 26% decrease of export sales.

SOPHARMA AD hereby informs that from 3 September 2015 up to and including 9 September 2015 the Company bought 43 614 own shares representing 0.032% of the share capital of the Company.

The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.

The total number of treasury shares after these transactions is 5 219 296, representing 3.87% of the share capital of the Company.

The Board of Directors of Sopharma notifies that on its meeting carried out on September 18, 2015 it took a decision to initiate a procedure for merging Momina krepost AD, VAT number 104055543 based in the city of Veliko Tarnovo on 23, “Magistralna” Blvd. into Sopharma AD, under the regulation of the Commercial Code and art. 122 and the following of the Law on Public Offering of Securities and chooses “Elana Trading” AD VAT number 831470130, based on 4, Kuzman Shapkarev Str. for a consultant in relation to the merger.

The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that in order to facilitate the operational work of Sopharma AD, the Board of Directors decided to appoint Ivan Badinski, MPharm, director of Cooperation and Licenses, Sopharma AD as procurator of the company. Mr. Badinski has been working in Sopharma AD since 1997 as a member of the Board of Directors of the Company.